Chemotherapy works by attacking cells that divide rapidly, which is the defining trait of cancer cells. But it can’t distinguish cancer from other fast-growing cells in your body, so it also damages healthy tissue in the hair follicles, digestive tract, bone marrow, and reproductive organs. That collateral damage is what causes most of the side effects people associate with chemo.
How Chemo Targets Cancer Cells
Cancer cells grow and divide faster than most normal cells, and chemotherapy drugs exploit that vulnerability. Different drugs attack at different stages of the cell cycle. Some bind directly to DNA, creating breaks and cross-links that prevent the cell from copying itself. Others block enzymes the cell needs to build new DNA, essentially starving the replication process. A third group interferes with the internal scaffolding (called microtubules) that pulls chromosomes apart when a cell divides, so the cell gets stuck mid-division and dies.
Most chemo regimens combine drugs that work through different mechanisms. This hits cancer cells at multiple points in their life cycle, making it harder for them to survive or develop resistance.
Why Healthy Cells Get Caught in the Crossfire
The cells most vulnerable to chemo are the ones that also divide quickly: cells lining the mouth and gut, hair follicle cells, bone marrow cells that produce blood, and reproductive cells. These tissues naturally replace themselves on a fast schedule, so they look a lot like cancer cells to a drug designed to attack rapid division. That’s why side effects tend to cluster in these specific systems rather than affecting the body uniformly.
Blood and Immune System
Bone marrow is one of the hardest-hit tissues because it constantly churns out new blood cells. Chemo slows that production, causing drops in white blood cells, red blood cells, and platelets. White blood cell and platelet counts typically start falling 7 to 10 days after a treatment cycle and hit their lowest point, called the nadir, around 7 to 14 days after treatment.
Low white blood cells (a condition called neutropenia) leave you significantly more vulnerable to infections. Low red blood cells contribute to anemia and fatigue. Low platelets mean your blood doesn’t clot as well, so you bruise more easily and cuts take longer to stop bleeding. Counts usually recover before the next cycle begins, but this temporary window of suppression is one of the most medically significant effects of chemo.
Digestive System
The lining of your gastrointestinal tract replaces itself every few days, making it especially sensitive to chemo drugs. When treatment damages the stem cells deep in the intestinal lining, it triggers a cascade: the body generates inflammatory molecules and reactive oxygen species, which cause further tissue injury. The result can be ulceration, thinning of the intestinal walls, and breakdown of the barrier that normally keeps gut bacteria contained.
This is what’s behind the mouth sores (mucositis), nausea, and diarrhea that many patients experience. The inflammation also disrupts normal nutrient absorption, which compounds fatigue and weight loss. Nausea can begin within hours of a treatment session and may persist for days, though anti-nausea medications have improved substantially and can blunt the worst of it.
Fatigue and Energy
Fatigue is the most common side effect of chemotherapy, reported by roughly 80% of patients receiving treatment. It’s not ordinary tiredness. Cancer-related fatigue has multiple physiological drivers working simultaneously.
Chemo raises levels of inflammatory molecules called cytokines, which directly alter neurotransmitter levels in the brain. Serotonin and its precursor tryptophan spike dramatically, contributing to both depression and exhaustion. Those same inflammatory molecules disrupt the body’s internal clock, interfering with sleep quality and the normal circadian rhythm. At the muscle level, chemo can damage the cellular machinery responsible for muscle contraction and regeneration, reducing your physical capacity even when you feel motivated to move. Roughly a third of cancer survivors continue to experience significant fatigue even after treatment ends.
Hair and Skin Changes
Hair follicle cells are among the fastest-dividing cells in the body, which makes them a predictable target. Hair usually begins falling out 2 to 4 weeks after treatment starts. The loss can be gradual or happen in clumps, and it may affect the scalp, eyebrows, eyelashes, and body hair depending on the drug regimen.
The good news is that hair loss from chemo is almost always temporary. You can expect regrowth to begin 3 to 6 months after your final treatment. The new hair may initially grow back with a different texture or color than before, though it typically returns to normal over time.
Nerve Damage
Chemotherapy-induced peripheral neuropathy affects anywhere from 19% to 85% of patients, depending on the drug and dose. It shows up as tingling, numbness, burning, or pain in the hands and feet.
The peripheral nervous system is especially vulnerable because it lacks an effective protective barrier against chemicals circulating in the blood. Chemo drugs can destabilize the internal structure of nerve fibers and cause swelling in the mitochondria (the energy-producing components inside nerve cells). This leads to progressive degeneration of sensory nerve fibers. The damage can affect fine motor skills, balance, and your ability to sense temperature or texture. For some people, neuropathy resolves after treatment ends. For others, it persists for months or years.
Cognitive Effects
The phenomenon commonly called “chemo brain” involves difficulty with memory, concentration, multitasking, and word-finding. Estimates of how many patients experience it vary widely. In one large survey of over 1,600 cancer survivors (mostly breast cancer), 75% reported cognitive complaints. When researchers use formal neuropsychological testing rather than self-reports, the numbers come in lower, typically between 15% and 34%, suggesting that some cognitive changes are subtle enough to miss on standardized tests but still noticeable in daily life.
Many patients see improvement within about 6 months of finishing treatment, but studies have found that 46% to 60% of affected patients have symptoms that linger beyond that point.
Reproductive System and Fertility
Chemo poses a real risk to fertility in both men and women, and the effects can be permanent depending on the drugs used and the total dose.
In women, certain drug classes (particularly alkylating agents) damage the eggs stored in the ovaries in a dose-dependent way. This can trigger premature ovarian insufficiency, essentially pushing the ovaries into early menopause. The risk increases with higher cumulative doses. In men, chemo can destroy the stem cells responsible for sperm production, impair ejaculatory function, and disrupt the hormonal signals that drive sperm development. Some drugs also cause genetic damage to sperm produced during and shortly after treatment.
Fertility preservation is most effective when done before treatment begins. For men, sperm banking is straightforward and well-established, with pregnancy rates of about 28% when banked sperm is later used. For women, embryo freezing yields pregnancy rates around 49% and live birth rates of 35% to 41%. If sperm production doesn’t recover after chemo, surgical sperm retrieval succeeds in 37% to 44% of men with persistent infertility.
Heart and Organ Stress
Certain chemo drugs carry known risks to the heart and kidneys. Heart damage (cardiotoxicity) can manifest as weakened pumping ability, irregular rhythms, or inflammation of the heart muscle. Some of these effects appear during treatment, while others may not surface until months or years later. Kidney toxicity is also a concern with specific drug classes, since the kidneys filter chemo drugs out of the blood and are exposed to high concentrations.
Medical teams monitor organ function throughout treatment with blood tests and, when needed, imaging of the heart. Dosing adjustments are made if signs of organ stress appear. For patients receiving drugs with known cardiac risks, baseline heart function testing before treatment starts is standard practice.